Dermatological Disorders

Lebrikizumab is a novel humanized monoclonal antibody that selectively inhibits interleukin-13.

Greater improvement seen in disease severity by 12 weeks with ciclosporin, but MTX was superior by 60 weeks.

NexoBrid (anacaulase-bcdb) is now available for eschar removal in adults with deep partial thickness and/or full thickness thermal burns.

It was found that 47.2% received no treatment on day of diagnosis; by one year, 71.8% were not receiving treatment.

The INTEGUMENT-PED trial included 652 children 2 to 5 years of age with mild to moderate atopic dermatitis who had a mean BSA of 22% and a range from 3% to 82%.

StrataGraft is a regenerative skin tissue therapy.

Higher proportion of vitamin D deficiency seen among those with more body surface area affected by psoriasis.

Risankizumab is an interlekin-23 inhibitor; apremilast is a phosphodiesterase 4 inhibitor.

Ycanth is expected to be available by September 2023.

The Company has decided to discontinue additional clinical studies of QTORIN 3.9% rapamycin anhydrous gel for pachyonychia congenita.

Study shows safety and tolerability of JAK inhibitors acceptable.

The treatment bar will be available at major retailers across the country.

No new safety signals were observed in this patient population.

The table below is a review of notable updates that occurred in June 2023 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

The biosimilar products are indicated for treating certain inflammatory diseases.

New approvals for alopecia, generalized myasthenia gravis and type 1 diabetes; A new osmotic laxative colonoscopy prep; FDA deny approval for a treatment for pre-cirrhotic fibrosis.

Longer median time of flare-free maintenance, greater number of flare-free days, and lower mean number of flares.